Skip to main content
SpringerLink
Log in

Multiple myeloma with IGH-FGFR3 rearrangement progressing as testicular plasmacytoma during carfilzomib treatment

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE (2017) Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv 1:282–287. https://doi.org/10.1182/bloodadvances.2016002493

    Article  PubMed  PubMed Central  Google Scholar 

  2. Sonneveld P, Westin J, Shimizu K, Morgan G, Greipp PR, Durie BGM, Ludwig H, Avet-Loiseau H, Kyle RA, Powles R, Shustik C, Child JA, Bladé J, Turesson I, Lahuerta JJ, Barlogie B, Miguel JS, Boccadoro M, Crowley JJ, Tosi P (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420. https://doi.org/10.1200/jco.2005.04.242

    Article  PubMed  Google Scholar 

  3. Alexiou C, Kau RJ, Dietzfelbinger H, Kremer M, Spiess JC, Schratzenstaller B, Arnold W (1999) Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. Cancer 85:2305–2314

    Article  CAS  PubMed  Google Scholar 

  4. Lazzarino M, Pica G, Varettoni M, Mangiacavalli S, Corso A, Pascutto C (2009) Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 21:325–330. https://doi.org/10.1093/annonc/mdp329

    Article  PubMed  Google Scholar 

  5. Rosenberg S, Shapur N, Gofrit O, Or R (2010) Plasmacytoma of the testis in a patient with previous multiple myeloma: is the testis a sanctuary site? J Clin Oncol 28:e456–e458. https://doi.org/10.1200/jco.2009.27.6519

    Article  PubMed  Google Scholar 

  6. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, Cortelazzo S, Ferreri AJM, Ambrosetti A, Martelli M, Thiéblemont C, Moreno HG, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea V, Roy P, Cavalli F, Gospodarowicz MK (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the international extranodal lymphoma study group. J Clin Oncol 21:20–27. https://doi.org/10.1200/JCO.2003.11.141

    Article  CAS  PubMed  Google Scholar 

  7. Sonneveld P, Lonial S, Usmani S, Siegel D, Anderson KC, Van De Donk NWCJ, Einsele H, Blad J, Palumbo A, Orlowski R (2017) Perspectives treatment of multiple myeloma with high-risk cytogenetics : a consensus of the international myeloma working group. Blood 127:2955–2963. https://doi.org/10.1182/blood-2016-01-631200.BLOOD

    Article  Google Scholar 

  8. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM (2003) In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood 101:1520–1529. https://doi.org/10.1182/blood-2002-06-1675

    Article  CAS  Google Scholar 

  9. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa A-M, Hulin C, Facon T, Attal M, Minvielle S, Harousseau J-L (2010) Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 28:4630–4634. https://doi.org/10.1200/JCO.2010.28.3945

    Article  CAS  PubMed  Google Scholar 

  10. Avet-Loiseau H, Fonseca R, Siegel D, Dimopoulos MA, Špička I, Masszi T, Hájek R, Rosiñol L, Goranova-Marinova V, Mihaylov G, Maisnar V, Mateos M-V, Wang M, Niesvizky R, Oriol A, Jakubowiak A, Minarik J, Palumbo A, Bensinger W, Kukreti V, Ben-Yehuda D, Stewart AK, Obreja M, Moreau P (2016) Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128:1174–1180. https://doi.org/10.1182/blood-2016-03-707596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan

    Nobuhiko Nakamura, Dai Maruyama, Yo Saito, Takahiro Fujino, Yuta Ito, Shunsuke Hatta, Shinichi Makita, Suguru Fukuhara, Wataru Munakata, Tatsuya Suzuki & Koji Izutsu

  2. Department of Pathology and Clinical Laboratory, National Cancer Center Hospital, Tokyo, Japan

    Akiko Miyagi Maeshima

  3. Department of Urology, National Cancer Center Hospital, Tokyo, Japan

    Hiroyuki Fujimoto

Authors
  1. Nobuhiko Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dai Maruyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Akiko Miyagi Maeshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yo Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takahiro Fujino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuta Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shunsuke Hatta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shinichi Makita
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Suguru Fukuhara
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Wataru Munakata
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tatsuya Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroyuki Fujimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Koji Izutsu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dai Maruyama.

Ethics declarations

Conflict of interest

Dai Maruyama has received honoraria and research funding from Janssen, Celgene, Ono, and Bristol-Myers Squibb Japan.

Informed consent

Informed consent to publish case details was obtained from the patient.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, N., Maruyama, D., Maeshima, A.M. et al. Multiple myeloma with IGH-FGFR3 rearrangement progressing as testicular plasmacytoma during carfilzomib treatment. Ann Hematol 98, 2463–2465 (2019). https://doi.org/10.1007/s00277-019-03743-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03743-6

Search

Navigation